Background : Previously we reported the inhibition of coronary restenosis with Abciximab(ReoPro)-coated stent. This study investigated the clinical outcomes of patients with acute myocardial infarction (AMI) treated with ReoPro-coated stents. Methods: We performed a prospective randomized trial to compare two types of stents for the revascularization in 63 patients [Group I (ReoPro-coated stent): n=32, 53.7짹11.8 years 27 male, and Group II (control stent): n=31, 55.4짹12.1 years, 27 male] with AMI. The primary effective end points were major adverse coronary events (MACE): cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at 1 year clinical and angiographic follow-up. Results : Baseline clinical characteristic, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. There was one myocardial infarction and revascularization during hospital stay in group II. Follow-up coronary angiogram was done 71.9% (23/32) in group I and 77.4% (24/31) in group II. Diameter stenosis and late loss were significantly lower in the group I compared with group II (19.4짹5.1% vs. 34.8짹5.9%, p=0.013; and 0.39짹0.26 mm vs. 0.89짹0.45 mm; p=0.008, respectively). But, the restenosis rates were not different between the two groups(21.7% vs. 37.5%, p=0.341). During clinical follow-up for 1 year at 98.4%(62/63), there were two AMI in group II and no AMI in group I. The TLR rates and total MACE of group I were relatively lower compared with group II [12.9% (4/31) vs. 29.0% (9/31); p=0.122 and 12.9% (4/31) vs. 35.5% (11/31), p=0.038, respectively]. Conclusion : The ReoPro-coated stent was safe without stent thrombosis and effective in patients with AMI.